Clinical Trial Information Request for Protocol 25-725 Title A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone